- Home
- MYSE vs TOVX Comparison
MYSE vs TOVX Comparison
Compare MYSE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYSE | TOVX |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | MYSE | TOVX |
|---|---|---|
| Price | $1.72 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 51.6K | ★ 8.8M |
| Earning Date | 05-14-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.55 | $0.16 |
| 52 Week High | $3.40 | $1.50 |
Technical Indicators
Market Signals| Indicator | MYSE | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 62.97 |
| Support Level | $1.68 | $0.17 |
| Resistance Level | $2.13 | $0.26 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 34.55 | 45.33 |
Price Performance
Historical ComparisonAbout MYSE Myseum Inc.
Myseum Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.